{"product_id":"nrxs-ansoff-analysis","title":"(NRXS) NeurAxis, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis NeurAxis, Inc. Ansoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification in a concise framework; the page already includes a real preview\/sample of the analysis so you can judge format and insight before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix for strategy, research, or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIB-Stim 11-18 share growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIB-Stim is NeurAxis, Inc.'s core commercial product for functional abdominal pain associated with IBS in patients aged 11 to 18, so market penetration means selling more of the same device in the same indication. The fastest path is deeper use inside existing hospital and clinic accounts, where added prescribing can lift share without new-label risk. One product, one patient pool, more repeat access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital account depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis already sells to hospitals and clinics, so hospital account depth means more units, more repeat orders, and more sites of care inside the same accounts. That matters because the 2025 push can scale from existing provider relationships instead of adding new buyers, which usually lowers sales cost per account and supports steadier revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric GI referral capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIB-Stim is labeled for patients ages 11 to 18, so pediatric GI referral capture fits the product’s core workflow. More referrals from pediatric gastroenterology specialists can lift treated volume without changing the device or the label, which is classic market penetration. In a market where the addressable group is still narrow, this is the fastest share-building move for NeurAxis, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProvider education for functional pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurAxis can widen market penetration by educating pediatric providers on functional abdominal pain and IBS symptom care, since these disorders affect about 13% to 25% of children and adolescents. More awareness can lift trial and conversion in physicians already treating the target age group, while staying in the same disease state and device category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets existing pediatric prescribers\u003c\/li\u003e\n\u003cli\u003eRaises awareness of symptom management\u003c\/li\u003e\n\u003cli\u003eSupports trial and conversion\u003c\/li\u003e\n\u003cli\u003eStays within current indication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess and reimbursement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess and reimbursement support is the fastest market-penetration lever for NeurAxis, Inc. because hospital and clinic adoption depends on patient access and payer acceptance. By helping secure coverage for the current IB-Stim offering, the Company can convert more eligible 11 to 18 year patients without changing the product. This is commercial execution, not product expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves payer approval rates\u003c\/li\u003e\n\u003cli\u003eSupports clinic adoption\u003c\/li\u003e\n\u003cli\u003eExpands use in 11 to 18 year patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurAxis Growth: Deeper Pediatric GI Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for NeurAxis, Inc. means pushing IB-Stim deeper into existing pediatric GI accounts, not changing the product or label. The Company can grow by raising repeat use, referral capture, and payer approval for patients aged 11 to 18. That fits a narrow, current market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget age\u003c\/td\u003e\n\u003ctd\u003e11-18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget condition\u003c\/td\u003e\n\u003ctd\u003eIBS pain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChild prevalence\u003c\/td\u003e\n\u003ctd\u003e13%-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenetration lever\u003c\/td\u003e\n\u003ctd\u003eRepeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing NeurAxis, Inc.’s business growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear NeurAxis, Inc. Ansoff Matrix snapshot that relieves strategy confusion and speeds growth planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources for NeurAxis, Inc. to validate Ansoff Matrix growth assumptions and speed due diligence with traceable references.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMore U.S. geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc., based in Carmel, Indiana, can grow IB-Stim by reaching more U.S. geographies without changing the device. The U.S. market spans 50 states and about 330 million people, so the same cleared product can be sold into new provider networks and hospital systems. That is market development: wider coverage, same IB-Stim. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew hospital systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc. can treat new hospital systems as a market development move because it already sells to hospitals, so the shift is deeper account penetration, not a new device launch. One multi-site system can open access to more pediatric patients across several facilities, boosting reach from one selling effort. That matters because one contract can scale use without adding new product cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew clinic networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew clinic networks fit NeurAxis, Inc.'s market development play because clinics already sit in its customer mix, so the next step is wider outpatient adoption. IB-Stim can be sold to more pediatric GI and pain clinics that treat functional abdominal pain, using the same FDA-cleared product in a larger buyer base. That is new market coverage, not a new product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty provider expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurAxis, Inc.'s market development play is to keep IB-Stim unchanged and place it with more pediatric GI specialty clinics, pain practices, and hospital-based specialists that already see functional abdominal pain patients. Since IB-Stim is a physician-prescribed device for patients ages 8 to 21, the real growth lever is a wider buying center, not consumer demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, broader specialty sites\u003c\/li\u003e\n\u003cli\u003eTargets pediatric GI pain patients\u003c\/li\u003e\n\u003cli\u003eExpands provider access, not use case\u003c\/li\u003e\n\u003cli\u003eSupports sales without changing the device\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader U.S. referral pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBroader U.S. referral pathways can lift NeurAxis, Inc. patient flow without changing the indication, by steering more children from pediatric primary care and specialty clinics into hospitals and practices already in its market.\u003c\/p\u003e\n\u003cp\u003eThat widens access for existing accounts, raises eligible patient volume, and can shorten time to treatment when clinicians know the referral path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore referrals to current accounts\u003c\/li\u003e\n\u003cli\u003eUses the same approved indication\u003c\/li\u003e\n\u003cli\u003eExpands route to treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurAxis Expands IB-Stim by Adding More Sites, Not New Uses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc. can grow IB-Stim by adding more U.S. hospital systems, pediatric GI clinics, and pain practices without changing the device. With the same FDA-cleared product for ages 8 to 21, market development means wider referral reach and more accounts, not a new use case.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket scope\u003c\/td\u003e\n\u003ctd\u003e50 U.S. states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget age group\u003c\/td\u003e\n\u003ctd\u003e8 to 21\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth move\u003c\/td\u003e\n\u003ctd\u003eSame product, more sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eNeurAxis, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIB-Stim platform extensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc. should use IB-Stim as the base for product development by adding next-gen features, better comfort, and smarter clinician tools around the same therapy. That fits its current pediatric base, including patients ages 8 to 21, and keeps expansion close to the 2 cleared pain indications already tied to IB-Stim.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel expansion studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis’s current IB-Stim is cleared for pediatric functional abdominal pain associated with IBS in patients 8-21, so label expansion studies can add use cases in functional GI care for the same hospitals and clinics. In a U.S. market where about 1 in 6 children has a functional GI disorder, broader evidence could deepen adoption without changing the core product. That is product development, not market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccessory and kit upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccessory and kit upgrades can drive IB-Stim adoption without changing the core device, by improving application kits, training, and clinic workflow tools. IB-Stim is already FDA-cleared for short-term treatment of pain associated with irritable bowel syndrome in patients 8 to 21, so lowering setup friction can help current-site uptake. For NeurAxis, Inc., this is a low-cost product-development lever inside an existing market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical workflow tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical workflow tools fit NeurAxis, Inc.’s product-development path because IB-Stim is a 5-day therapy that hospitals and clinics can deploy more smoothly with simple setup, tracking, and support. For existing providers, better workflow support can lift adherence and reduce variation without changing the core customer segment.\u003c\/p\u003e\n\u003cp\u003eThat matters because NeurAxis, Inc. is selling into care teams that need repeatable processes, not just the device. A tighter workflow layer can improve training, scheduling, and follow-up for the same IB-Stim use case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports existing hospital and clinic users\u003c\/li\u003e\n\u003cli\u003eImproves consistency across IB-Stim care\u003c\/li\u003e\n\u003cli\u003eFits product development, not new markets\u003c\/li\u003e\n\u003cli\u003eMatches a 5-day therapy workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-gen neuromodulation design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurAxis’s neuromodulation focus makes next-gen IB-Stim a natural product-development step for the same pediatric group, ages 8 to 21. A newer version can improve wear comfort, setup, and treatment support while keeping the core market in place.\u003c\/p\u003e\n\u003cp\u003eThis fits Ansoff product development because the buyer base stays the same while the device gets better. It also builds on the FDA-cleared IB-Stim platform, which was designed for functional abdominal pain related to irritable bowel syndrome.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame pediatric market\u003c\/li\u003e\n\u003cli\u003eBetter usability and support\u003c\/li\u003e\n\u003cli\u003eLower launch risk than new markets\u003c\/li\u003e\n\u003cli\u003eClear fit with iterative device design\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurAxis Bets on IB-Stim Upgrades, Not New Buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc.’s product development path is to upgrade IB-Stim for the same pediatric market, not chase new buyers. The device already serves patients ages 8 to 21 and stays tied to FDA-cleared IBS-related pain use, so gains should come from comfort, workflow, and label expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent base\u003c\/td\u003e\n\u003ctd\u003eAges 8 to 21\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy length\u003c\/td\u003e\n\u003ctd\u003e5 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCleared use\u003c\/td\u003e\n\u003ctd\u003eIBS-related pain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePath\u003c\/td\u003e\n\u003ctd\u003eNext-gen IB-Stim upgrades\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther functional GI indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis, Inc. is still concentrated on pediatric IBS-related abdominal pain, so diversification would mean entering other functional GI indications such as functional dyspepsia or functional abdominal pain. Pediatric functional GI disorders affect up to 25% of children, so the addressable market is broader, but each use case needs its own clinical positioning and may need new approvals. That shifts NeurAxis, Inc. into a new product-use profile and a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult patient markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIB-Stim is currently positioned for patients ages 11 to 18, so moving into adult patients would open a new customer base and a new use case. That makes it a true diversification play in Ansoff terms, since both the buyer group and the medical indication change. In 2025, NeurAxis reported $2.3 million in Q1 revenue, showing how early the base is for any adult expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader chronic pain categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurAxis’s neuromodulation know-how could move IB-Stim from pediatric functional abdominal pain into broader chronic pain categories, a true new-market, new-product step. CDC data show 51.6 million U.S. adults had chronic pain in 2021, so the addressable pool is far larger than the current pediatric GI niche. If NeurAxis can translate its non-drug stimulation model into other pain syndromes, it could widen revenue well beyond one indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital therapy support offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurAxis, Inc. can use digital therapy support as a diversification layer by adding patient education, symptom tracking, and remote follow-up around its core device. That shifts the offer beyond hospitals and clinics and can reduce reliance on one product line, which matters when a single-device model drives most revenue.\u003c\/p\u003e\n\u003cp\u003eIt also fits a broader market reach, since digital support can be sold to caregivers, telehealth teams, and payers, not just prescribers. One clear sign of the model’s appeal: digital therapeutics and remote monitoring are now being used to extend care between visits, where adherence and outcomes often slip.\u003c\/p\u003e\n\u003cp\u003eFor NeurAxis, the best use is not replacing the device but pairing it with software that keeps patients engaged after launch. That makes the business less tied to one treatment cycle and more able to capture recurring service use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew layer: education, monitoring, support\u003c\/li\u003e\n\u003cli\u003eBroader buyers: patients, payers, telehealth\u003c\/li\u003e\n\u003cli\u003eLess dependence on one device line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdditional neuromodulation portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurAxis, Inc. has a concentrated product base, with most sales tied to a single neuromodulation offering. A second neuromodulation family for a different clinical need or customer group would be the cleanest way to cut single-product risk and widen the addressable market. For context, the company reported $7.1 million in revenue in 2024, so even modest line expansion can matter.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces dependence on one product\u003c\/li\u003e\n\u003cli\u003eTargets a new patient group\u003c\/li\u003e\n\u003cli\u003eSpreads regulatory and reimbursement risk\u003c\/li\u003e\n\u003cli\u003eFits a higher-growth diversification move\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurAxis’s Growth Path: Diversifying Beyond Pediatric IBS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification for NeurAxis, Inc. means moving beyond pediatric IBS into new indications, ages, or digital care layers. That is a true Ansoff diversification step because it changes both the product-use case and the market, while the 2025 Q1 revenue of $2.3 million and 2024 revenue of $7.1 million show how early the base still is.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult pain\u003c\/td\u003e\n\u003ctd\u003eNew buyer, new use\u003c\/td\u003e\n\u003ctd\u003e51.6M U.S. adults had chronic pain in 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew GI indications\u003c\/td\u003e\n\u003ctd\u003eNew clinical niche\u003c\/td\u003e\n\u003ctd\u003ePediatric FGI disorders affect up to 25% of children\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital support\u003c\/td\u003e\n\u003ctd\u003eAdds recurring service\u003c\/td\u003e\n\u003ctd\u003eCan broaden use beyond one device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234770755849,"sku":"nrxs-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nrxs-ansoff-matrix.webp?v=1785726694","url":"https:\/\/dcfanalyst.com\/products\/nrxs-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}